Incidence and risk factors for oxaliplatin-induced vascular pain during administration in Iraqi patients

  • Yaala Saady Raof Al-Bairmany Al-Andalus Private Hospital for Cancer Patients, Baghdad, Iraq
  • Noor Kasib Hadi Al Yarmook Teaching Hospital, Baghdad, Iraq
  • Mays Alrubayi Al Amal National Oncology Hospital, Baghdad, Iraq
Keywords: Incidence, risk factors, oxaliplatin, vascular pain, Iraq

Abstract

Introduction: The primary objective of this study was to identify the percentage of oxaliplatin-induced vascular pain during administration in Iraqi patients. The secondary objective was to identify the risk factors for vascular pain.

Methods: This is a cross-sectional observational study carried out at the Al-Andalus private hospital for cancer patients, Baghdad, Iraq. The study included 101 patients, diagnosed with one of the following cancers: colon, pancreatic, stomach, and rectal cancer, ranging from 18 to 80 years, and receiving oxaliplatin peripheral venous infusion.  Data collected included: age, gender, diagnosis, history of chronic disease, treatment protocol, degree of pain severity, cancer stage, history of previous vascular pain, number of cycles, the incidence of vascular pain, oxaliplatin dose.

Results: Sixty-two patients out of 101 patients had experienced vascular pain during oxaliplatin peripheral venous infusion, representing about (61.4 %). History of diabetes mellitus was significantly associated with vascular pain induction (OR=1.59, [CI: 1.07 - 2.39]). The age group from 40-60 years old was significantly associated with 59 % higher odds of vascular pain (OR=1.59, CI: 1.07 - 2.39) than other age groups. Female patients were significantly associated with 59 % higher odds of vascular pain (OR=1.59, CI: 1.07 - 2.39) than males.

Conclusion: The results of this study indicate that history of diabetes mellitus, the age group from 40-60 years old, and female gender are risk factors for oxaliplatin-induced vascular pain in patients with GI malignancy. These findings could be useful to assess the risk of vascular pain in clinical settings.

Author Biographies

Yaala Saady Raof Al-Bairmany, Al-Andalus Private Hospital for Cancer Patients, Baghdad, Iraq

Head of the Medical Oncology Department

Noor Kasib Hadi, Al Yarmook Teaching Hospital, Baghdad, Iraq

Medical Oncology Resident

Mays Alrubayi , Al Amal National Oncology Hospital, Baghdad, Iraq

General Pharmacist

References

Ali, N. T., Mohamed, A. A., & Yousef, B. A. (2020). The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey. Asia Pac J Oncol Nurs, 7(3), 266-272.

Atisook, R., Euasobhon, P., Saengsanon, A., & Jensen, M. P. (2021). Validity and Utility of Four Pain Intensity Measures for Use in International Research. J Pain Res, 14, 1129-1139.

Delgado, D. A., Lambert, B. S., Boutris, N., McCulloch, P. C., Robbins, A. B., Moreno, M. R., & Harris, J. D. (2018). Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev, 2(3), e088.

Devanabanda, B., & Kasi, A. (2021). Oxaliplatin. In StatPearls.

Hata, T., Honda, M., Kobayashi, M., Toyokawa, A., Tsuda, M., Tokunaga, Y., Takase, K., Miyake, M., Morita, S., Nagata, N., Sakamoto, J., Gosho, M., & Mishima, H. (2015). Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO). Cancer Chemother Pharmacol, 76(6), 1209-1215.

Kawazoe, H., Sumikawa, S., Nakauchi, K., Yakushijin, Y., Yamamoto, Y., Watanabe, Y., Tanaka, A. and Araki, H. (2017). Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain. International Journal of Clinical Pharmacy.

Matsuyama, K., Mishima, H., Ueno, H., Kajihara, K., Morioka, A., Morimoto, S., Yamauchi, K., Honda, Y., Komori, K., & Tsujinaka, T. (2011). [Etiology and management of venous pain during intravenous administration of oxaliplatin]. Gan To Kagaku Ryoho, 38(3), 411-414.

Miyajima, R., Kawazoe, H., Tsuneoka, K., Fujiwara, M., Kojima, Y., & Yakushijin, Y. (2013). [Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain]. Gan To Kagaku Ryoho, 40(4), 537-540.

Mizrahi, D., Park, S. B., Li, T., Timmins, H. C., Trinh, T., Au, K., Battaglini, E., Wyld, D., Henderson, R. D., Grimison, P., Ke, H., Geelan-Small, P., Marker, J., Wall, B., & Goldstein, D. (2021). Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Netw Open, 4(2), e2036695.

Nagao, S., Furihata, M., Fukagawa, K., Furihata, T., Matsuhashi, Y., & Wada, T. (2017). Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. J Infect Chemother, 23(7), 493-497.

Petrelli, F., Coinu, A., Ghilardi, M., Cabiddu, M., Zaniboni, A., & Barni, S. (2015). Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. Am J Clin Oncol, 38(2), 227-233.

Suga, Y., Ikeda, N., Maeda, M., Staub, A. Y., Shimada, T., Yonezawa, M., Kitade, H., Katsura, H., Okada, M., Ishizaki, J., Sai, Y., & Matsushita, R. (2018). Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods. J Pharm Health Care Sci, 4, 18.

Suwa, Y., Watanabe, J., Ota, M., Suzuki, S., Suwa, H., Watanabe, K., Saito, S., Nagamine, K., Momiyama, M., Ishibe, A., Saigusa, Y., Yamanaka, T., & Endo, I. (2019). Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205). Cancer Chemother Pharmacol, 83(3), 419-424.

Takagi A, Y. N., Aoyama Y, Touma Y, Kajiwara M, Watanabe K, et al,. (2015). Search for factors related to vascular pain expression upon administration of oxaliplatin into a peripheral vein. Japan J Cancer Chemother, 42:887–9.

Yoshida, Y., Hoshino, S., Aisu, N., Shiwaku, H., Beppu, R., Tanimura, S., & Yamashita, Y. (2012). Dexamethasone as a means for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein and also for controlling oxaliplatin-induced hypersensitivity reactions. Journal of Clinical Oncology, 30(4_suppl), 662-662.

Published
2022-03-01
How to Cite
1.
Saady Raof Al-Bairmany Y, Kasib Hadi N, Alrubayi M. Incidence and risk factors for oxaliplatin-induced vascular pain during administration in Iraqi patients. jpadr [Internet]. 2022Mar.1 [cited 2022May25];3(1):19-5. Available from: https://jpadr.com/index.php/jpadr/article/view/66